Why the study?
Ongoing CAD residual risk despite lipid-lowering therapy and ongoing controversy over using apoB as a therapeutic target in clinical practice motivated this review.
Design
Review
Authors
Loading...
ApoB may refine CV risk assessment over LDL-C; leaves open guideline substitution pending prospective validation.
Key points are not available for this paper at this time.
Behbodikhah et al. (2021) studied this question.